Scholarlink

<p>Early diagnosis and treatment of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) are essential because they directly impact patient quality of life. This report describes the case of an 85-year-old woman with type 2 diabetes on insulin therapy, whose glycemic fluctuations became highly unstable following irAE development. During treatment for refractory hepatocellular carcinoma with tremelimumab and durvalumab, she developed hyperglycemia and was hospitalized. Endogenous insulin secretion remained intact, and hyperglycemia improved after admission. Continuous glucose monitoring (CGM) revealed nocturnal and early-morning hypoglycemia from the fourth day of admission. Insulin requirements were tapered off; however, persistent anorexia and dyspnea led to the diagnosis of hypopituitarism through endocrine testing. For patients with diabetes who experience abnormal blood glucose fluctuations after ICI therapy, clinicians should monitor changes in endogenous insulin secretion and consider the possibility of hypoadrenocorticism. CGM may be valuable for detecting these endocrine abnormalities.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Blood glucose variability in early-onset adrenocorticotropic hormone deficiency induced by immune checkpoint inhibitor therapy with continuous blood glucose monitoring: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月12日

查看全文
  • Yuta Nanao,
  • Gentaro Egusa,
  • Ryuta Baba,
  • Takaya Kodama,
  • Tsuguka Matsuda,
  • Gaku Nagano,
  • Haruya Ohno

摘要

Early diagnosis and treatment of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) are essential because they directly impact patient quality of life. This report describes the case of an 85-year-old woman with type 2 diabetes on insulin therapy, whose glycemic fluctuations became highly unstable following irAE development. During treatment for refractory hepatocellular carcinoma with tremelimumab and durvalumab, she developed hyperglycemia and was hospitalized. Endogenous insulin secretion remained intact, and hyperglycemia improved after admission. Continuous glucose monitoring (CGM) revealed nocturnal and early-morning hypoglycemia from the fourth day of admission. Insulin requirements were tapered off; however, persistent anorexia and dyspnea led to the diagnosis of hypopituitarism through endocrine testing. For patients with diabetes who experience abnormal blood glucose fluctuations after ICI therapy, clinicians should monitor changes in endogenous insulin secretion and consider the possibility of hypoadrenocorticism. CGM may be valuable for detecting these endocrine abnormalities.